- Home
- HEPS vs LENZ Comparison
HEPS vs LENZ Comparison
Compare HEPS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- LENZ
- Stock Information
- Founded
- HEPS 2000
- LENZ 2019
- Country
- HEPS Turkey
- LENZ United States
- Employees
- HEPS N/A
- LENZ N/A
- Industry
- HEPS Catalog/Specialty Distribution
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- HEPS Consumer Discretionary
- LENZ Health Care
- Exchange
- HEPS Nasdaq
- LENZ Nasdaq
- Market Cap
- HEPS 876.9M
- LENZ 795.5M
- IPO Year
- HEPS 2021
- LENZ 2021
- Fundamental
- Price
- HEPS $2.61
- LENZ $26.34
- Analyst Decision
- HEPS
- LENZ Strong Buy
- Analyst Count
- HEPS 0
- LENZ 5
- Target Price
- HEPS N/A
- LENZ $41.80
- AVG Volume (30 Days)
- HEPS 421.7K
- LENZ 259.1K
- Earning Date
- HEPS 06-12-2025
- LENZ 05-07-2025
- Dividend Yield
- HEPS N/A
- LENZ N/A
- EPS Growth
- HEPS N/A
- LENZ N/A
- EPS
- HEPS N/A
- LENZ N/A
- Revenue
- HEPS $1,612,901,778.00
- LENZ N/A
- Revenue This Year
- HEPS $22.80
- LENZ N/A
- Revenue Next Year
- HEPS $25.49
- LENZ $544.90
- P/E Ratio
- HEPS N/A
- LENZ N/A
- Revenue Growth
- HEPS 11.12
- LENZ N/A
- 52 Week Low
- HEPS $1.42
- LENZ $14.42
- 52 Week High
- HEPS $4.05
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- HEPS 43.55
- LENZ 52.07
- Support Level
- HEPS $2.43
- LENZ $22.52
- Resistance Level
- HEPS $2.66
- LENZ $27.37
- Average True Range (ATR)
- HEPS 0.12
- LENZ 2.19
- MACD
- HEPS 0.00
- LENZ -0.14
- Stochastic Oscillator
- HEPS 32.73
- LENZ 47.99
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues, and other revenues.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.